SRA's number for the day: 4
This article was originally published in SRA
The European Medicines Agency is being reorganized and will soon have four new divisions focussing on: supporting the R&D phase in drug companies; medicines evaluation and lifecycle management; procedure management and business data; and inspections and pharmacovigilance1.
You may also be interested in...
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.
The European Medicines Agency may decide this week on a dozen requests by companies seeking new uses of their approved drugs.